Table 2.
Patient selection from source population to matched cohorts in each dataset
| Cohort | Dataset | ||||||
|---|---|---|---|---|---|---|---|
| Finland | Sweden | Netherlands hospital | Netherlands GP | UK GP | UK GP-hospital | Total | |
| Diabetic patients who initiated or switched treatment | |||||||
| Source population | 438 229 | 295 001 | 208 962 | 63 284 | 317 632 | 306 301 | 1 629 409 |
| Eligible patients after applying all exclusion criteria | |||||||
| Exposed to pioglitazone | 18 794 | 3712 | 9081 | 2829 | 12 662 | 14 504 | 61 587 |
| Not exposed to pioglitazone | 332 255 | 224 742 | 131 028 | 42 174 | 70 471 | 78 037 | 878 707 |
| Cohort sizes after matching* | |||||||
| Exposed to pioglitazone | 18 794 | 3 712 | 7491 (8965) | 2823 | 11 408 | 12 109 | 56 337 |
| Not exposed to pioglitazone | |||||||
| Nearest matched cohort | 18 794 | 3 712 | 7491 (8965) | 2823 | 11 408 | 12 109 | 56 337 |
| Multiple matched cohort | 157 263 | 31 040 | 42 048 (50 493) | 15 775 | 35 799 | 35 184 | 317 109 |
*Numbers in parentheses are the cohort size before overlap between Netherland cohorts was removed.